Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
Portfolio Pulse from Vandana Singh
The COVAX initiative, run by Gavi, the WHO, and CEPI, has a $2.6 billion surplus that could be used for future pandemics or vaccine manufacturing in Africa. Around $600 million is allocated as a contingency fund, while $2 billion was refunded by drugmakers. Gavi is proposing a financial support system to help new manufacturers bring products to market competitively.
June 26, 2023 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Moderna is mentioned in the context of the COVAX initiative's surplus, which could potentially impact the company's involvement in future pandemic preparedness and vaccine manufacturing.
Moderna is mentioned in the context of the COVAX initiative's surplus, which could potentially impact the company's involvement in future pandemic preparedness and vaccine manufacturing. However, the direct impact on Moderna's stock price is uncertain.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Pfizer is mentioned in the context of the COVAX initiative's surplus, which could potentially impact the company's involvement in future pandemic preparedness and vaccine manufacturing.
Pfizer is mentioned in the context of the COVAX initiative's surplus, which could potentially impact the company's involvement in future pandemic preparedness and vaccine manufacturing. However, the direct impact on Pfizer's stock price is uncertain.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50